Progress against lung cancer, Denmark, 2008-2022.


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: Sweden
ID NLM: 8709065

Informations de publication

Date de publication:
14 May 2024
Historique:
received: 15 11 2023
accepted: 02 03 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 15 5 2024
Statut: epublish

Résumé

There has been marked progress against lung cancer in Denmark. To gain further insight into the different aspects of the improvement, we examined the stage-specific incidence rates, stage-specific survival and mortality rates. We used information from the Danish Lung Cancer Registry on date of diagnosis and clinical stage to calculate age-standardised incidence rates and patient survival by sex, period and stage. Information about age-standardised lung cancer-specific mortality rates by sex and period was extracted from The Danish Health Data Authority. Firstly, the decrease in incidence rates was due to a reduction in the rates of advanced stages. Secondly, there was a gradual increase in survival across all stages, and thirdly, the mortality rates gradually decreased over time. The improvements in survival and mortality from lung cancer were due to decreasing incidence rates of advanced cancer and improvement in survival at all stages of the disease.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
There has been marked progress against lung cancer in Denmark. To gain further insight into the different aspects of the improvement, we examined the stage-specific incidence rates, stage-specific survival and mortality rates.
MATERIALS AND METHODS METHODS
We used information from the Danish Lung Cancer Registry on date of diagnosis and clinical stage to calculate age-standardised incidence rates and patient survival by sex, period and stage. Information about age-standardised lung cancer-specific mortality rates by sex and period was extracted from The Danish Health Data Authority.
RESULTS RESULTS
Firstly, the decrease in incidence rates was due to a reduction in the rates of advanced stages. Secondly, there was a gradual increase in survival across all stages, and thirdly, the mortality rates gradually decreased over time.
INTERPRETATION CONCLUSIONS
The improvements in survival and mortality from lung cancer were due to decreasing incidence rates of advanced cancer and improvement in survival at all stages of the disease.

Identifiants

pubmed: 38745484
doi: 10.2340/1651-226X.2024.26180
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

339-342

Auteurs

Marianne Steding-Jessen (M)

The Danish Clinical Quality Program and Clinical Registries (RKKP), Aarhus, Denmark. masted@rkkp.dk.

Henriette Engberg (H)

The Danish Clinical Quality Program and Clinical Registries (RKKP), Aarhus, Denmark.

Erik Jakobsen (E)

Department of Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; The Danish Lung Cancer Registry (DLCR), Odense University Hospital, Odense, Denmark.

Torben Riis Rasmussen (TR)

Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark.

Henrik Møller (H)

The Danish Clinical Quality Program and Clinical Registries (RKKP), Aarhus, Denmark; Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH